Article
Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women.
Antiviral therapy - 1 Jan 2012
Palmer Sarah, Boltz Valerie F, Chow Jeremy Y, Martinson Neil A, McIntyre James A, Gray Glenda E, Hopley Mark J, Mayers Douglas, Robinson Patrick, Hall David B, Maldarelli Frank, Coffin John M, Mellors John W
Abstract excerpt
BACKGROUND: In the Treatment Options Preservation Study (TOPS) trial, 4 or 7 days of Combivir (CBV; zidovudine/lamivudine) with maternal single-dose nevirapine (sdNVP) significantly reduced the emergence of NVP resistance as determined by virus population genotyping. To detect NVP resistance with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
